Ownership and insider activity for AbbVie Inc. (ABBV): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active...
Price
| Price | $265.76 |
| Market Cap | $469.5B |
| Exchange | NYSE |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-30 | Quaggin Susan E | A-Award | 59 | $15K |
| 2026-09-30 | RAPP EDWARD J | A-Award | 129 | $34K |
| 2026-08-14 | Donoghoe Nicholas | M-Exempt | 32,710 | $2.6M |
| 2026-08-14 | Donoghoe Nicholas | S-Sale | 32,710 | $8.2M |
| 2026-08-14 | Donoghoe Nicholas | M-Exempt | 32,710 | $2.6M |
| 2026-06-30 | RAPP EDWARD J | A-Award | 134 | $34K |
| 2026-06-30 | Quaggin Susan E | A-Award | 62 | $16K |
| 2026-05-08 | FALK THOMAS J | A-Award | 1,118 | |
| 2026-05-08 | WADDELL FREDERICK H | A-Award | 1,118 | |
| 2026-05-08 | Roberts Rebecca B | A-Award | 1,118 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.10B | $9.30B | $7.29B | $39.92B | $8.45B | $9.75B | $9.20B | $12.81B | $5.52B | $5.23B |
| Short-term Investments | $1.32B | $486.0M | $772.0M | 0 | $30.0M | $84.0M | $28.0M | $2.0M | $31.0M | $28.0M |
| Receivables | $4.76B | $5.09B | $5.38B | $5.43B | $8.82B | $9.98B | $11.25B | $11.15B | $10.92B | $12.59B |
| Inventory | $1.44B | $1.60B | $1.60B | $1.81B | $3.31B | $3.13B | $3.58B | $4.10B | $4.18B | $4.95B |
| Total Current Assets | $16.19B | $21.22B | $16.95B | $49.52B | $24.17B | $27.93B | $28.46B | $33.00B | $25.58B | $29.06B |
| Property, Plant & Equipment | $2.60B | $2.80B | $2.88B | $2.96B | $5.25B | $5.11B | $4.93B | $4.99B | $5.13B | $6.37B |
| Goodwill | $15.42B | $15.79B | $15.66B | $15.60B | $33.12B | $32.38B | $32.16B | $32.29B | $34.96B | $35.64B |
| Intangible Assets | $28.90B | $27.56B | $21.23B | $18.65B | $82.88B | $75.95B | $67.44B | $55.61B | $60.07B | $52.64B |
| Total Assets | $66.10B | $70.79B | $59.35B | $89.11B | $150.56B | $146.53B | $138.81B | $134.71B | $135.16B | $133.96B |
| Accounts Payable | $1.41B | $1.47B | $1.55B | $1.45B | $2.28B | $2.88B | $2.93B | $3.69B | $2.94B | $3.59B |
| Short-term Debt | $402.0M | $6.42B | $5.31B | $3.75B | $8.68B | $12.67B | $4.30B | $7.19B | $6.80B | $8.75B |
| Total Current Liabilities | $9.78B | $16.64B | $17.24B | $15.59B | $28.66B | $35.19B | $29.54B | $37.84B | $38.75B | $43.29B |
| Long-term Debt | $36.44B | $30.95B | $35.00B | $62.98B | $77.53B | $64.16B | $59.12B | $52.17B | $60.34B | $59.61B |
| Total Liabilities | $61.46B | $65.69B | $67.80B | $97.29B | $137.47B | $131.09B | $121.52B | $124.31B | $131.80B | $137.19B |
| Retained Earnings | $4.38B | $5.46B | $3.37B | $4.72B | $1.05B | $3.13B | $4.78B | -$1.00B | -$7.90B | -$15.49B |
| Total Equity | $4.64B | $5.10B | -$8.45B | -$8.17B | $13.08B | $15.41B | $17.25B | $10.36B | $3.33B | -$3.27B |
| Total Debt | $36.84B | $37.37B | $40.31B | $67.09B | $87.06B | $77.58B | $64.19B | $60.12B | $67.84B | $69.07B |
| Net Debt | $30.42B | $27.58B | $32.25B | $27.16B | $78.58B | $67.75B | $54.96B | $47.30B | $62.29B | $63.81B |
| Working Capital | $6.41B | $4.58B | -$294.0M | $33.93B | -$4.49B | -$7.27B | -$1.07B | -$4.84B | -$13.17B | -$14.23B |
Financial Health
| Debt / Equity | -11.93 |
| Current Ratio | 0.81 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 2.43 |
Profitability
| Return on Equity | -136.50% |
| Return on Invested Capital | 13.46% |
| Return on Assets | 4.67% |
| Gross Margin | 71.48% |
| Operating Margin | 29.32% |
| Net Margin | 9.81% |
Related companies: AMGN · AZN · GILD · JNJ · MRK · NVO · NVS
Explore sector: Healthcare · Drug Manufacturers - General
More sections of ABBV: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks